Barry Festoff

20020111296, Aug 15, 2002

Aug 23, 2001

09/938405

Barry Festoff - Kansas City MO, US
Michael Morser - San Francisco CA, US

A61K038/17

514/008000

The present invention relates to the use of thrombomodulin analogs for the treatment of trauma-induced spinal cord injury.

20040002446, Jan 1, 2004

Apr 10, 2003

10/410195

Barry Festoff - Kansas City MO, US
Michael Morser - San Francisco CA, US

A61K038/36

514/008000

The present invention relates to the use of thrombomodulin analogs for the treatment of trauma-induced spinal cord injury.

20050272025, Dec 8, 2005

Aug 12, 2003

10/524060

Zhiming Suo - Kansas City MO, US
Barry Festoff - Kansas City MO, US

C12Q001/00
G01N033/53
G01N033/567

435004000, 435007200, 514012000

A method of detecting Alzheimer's disease includes detecting a disruption or alteration in normal sub-cellular distribution of G-protein receptor kinases (GRKs), particularly GRK2 and GRK5. The disruption is caused by abnormal accumulation of soluble β-amyloid. The prevention or suppression of the disease progression at prodromal or early stages includes correction of GRK dysfunction.

20090143281, Jun 4, 2009

Aug 22, 2008

12/197031

Barry W. FESTOFF - Kansas City MO, US
Michael J. Morser - San Francisco CA, US

A61K 38/16
A61P 25/00

514 8

The present invention relates to the use of thrombomodulin analogs for the treatment of trauma-induced spinal cord injury.

20230085593, Mar 16, 2023

Jun 10, 2022

17/837480

Barry W. FESTOFF - Kansas City MO, US

G01N 33/68
G16H 10/40
A61B 5/151
A61B 5/157
A61K 38/00
C07K 14/47
C07K 14/745
C12N 15/85
C12Q 1/6883

Blood and bodily fluid reader systems, including circulating biomarkers involving multiple mitochondrial releasates for providing real-time, at-the-scene objective indicia of individuals sustaining mild TBI.

20210140981, May 13, 2021

Apr 9, 2019

17/046606

Barry W. FESTOFF - Kansas City MO, US

G01N 33/68
C12Q 1/6883
C12N 15/85
C07K 14/745
C07K 14/47
A61K 38/00
A61B 5/157
A61B 5/151
G16H 10/40

Blood and bodily fluid reader systems, including circulating biomarkers involving multiple mitochondrial releasates for providing real-time, at-the-scene objective indicia of individuals sustaining mild TBI. As a therapeutic component for related neuroin-flammation of mild TBI and related injuries, medicaments, compounds and methods include chimeric proteins which combine: (i) a first polypeptide sequence derived from the “Box A” domain of the “High-Mobility Group Box 1” Protein ( HMGB1) protein; and, (ii) a second polypeptide sequence derived from the D1 lectin-like domain of thrombomodulin (TM). These chimeric proteins both activate and promote certain repair-type functions within the brain, up to and in some cases including the growth of new neuronal fibers and/or the creation of new synaptic junctions; and, keep those types of inflammation-triggered repair processes within healthy and desirable limits.

20190293663, Sep 26, 2019

Jan 11, 2014

14/153033

Barry W. Festoff - Kansas City MO, US

G01N 33/68

Methods and materials are disclosed for evaluating head brain injuries that do not involve blood loss or skull fractures, such as possible concussions. These methods and materials involve bioreagents (such as monoclonal antibodies, single-stranded DNA or RNA, etc.) affixed to computer-readable devices handled by electronic readers that can interact with portable computers (such as laptops, pads or tablets, smart phones, etc.). The bioreagents will detect the presence and concentration of at least two metabolites that are released by mitochondria in response to cellular damage. Additional bioreagents may be included, for detecting and quantifying other damage-associated molecular patterns (DAMP's). When used along with cognitive, reasoning, and/or response tests, this type of analysis can help non-physicians assess the severity of, and proper responses to, head traumas that otherwise are difficult or impossible to reliably evaluate.